spacer
home > ebr > spring 2007 > microfluidics: just a drop in the ocean?
PUBLICATIONS
European Biopharmaceutical Review

Microfluidics: Just a Drop in the Ocean?

Géraldine Andrieux-Gustin at Yole Développement charts microfluidics’ route to achieving its potential in the life science market

Microfluidics is an enabling technology with tremendous potential in many application fields. It adds value by providing key solutions required by the growing diagnostic market. This article presents an overview of microfluidic technologies and analyses factors that are currently driving businesses to success.

MICROFLUIDIC TECHNOLOGIES

Semiconductor lines were first used in the early development of microfluidic components on silicon as well as on glass. Since the 1990s polymer microtechnologies have emerged as a cost effective alternative to glass and silicon. Replication technologies have drastically decreased production costs, thereby opening the market for disposable microfluidic cartridges. Most microfluidic products are based on microchannels structuration; electro wetting on dielectric (EWOD) is a new alternative. The fluid actuation and control are based on electrodes, as illustrated in Figure 2.

MICROFLUIDIC COMPONENTS AND APPLICATION FIELDS

Microfluidic components are diverse and find applications in a broad range of fields – not just life sciences but also inkjet printing, electronics, petrochemistry, aerospace and more. Within life sciences, drug discovery is one of the main microfluidic markets. The competitive advantage of microfluidics is its ability to increase analysis throughput, while reducing reaction volume. Microfluidic components are also sold as cartridges, disks or chips for biological analysis, as illustrated in Figure 3. Microfluidics make it possible to integrate different protocols in one chip, to automate analysis and reduce reaction time. Microfluidics’ predominant area of growth is expected to be within the diagnostic market.

MICROFLUIDICS’DEVELOPMENT STATUS

Microfluidics’ proof-of-concept is validated according to the major companies involved in instrumentation, pharmaceuticals and diagnostics. Manufacturability, which was largely perceived as a technological weakness, has been improved, with production techniques proposed by companies such as 3M, Epigem and Dyconex. Microfluidics and associated business success stories also increase its perceived added value.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Géraldine Andrieux-Gustin was granted a Master’s degree in Technology and Innovation Management from EM Lyon Business School. She graduated in Biology from the University Paris VI and in Biochemistry (Biotechnology Option) from Carleton University, Canada. She has been involved in micro and nanotechnologies for five years, concentrating on microfluidics.
spacer
Géraldine Andrieux-Gustin
spacer
spacer
Print this page
Send to a friend
Privacy statement

Industry Events

Paediatric Clinical Trials

21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom

Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >>

 
News and Press Releases

AMRI Announces Preferred Provider Agreement with BioPontis Alliance LLC

AMRI, a global contract services organization, announced today that it has entered into a preferred provider agreement with BioPontis Alliance LLC. The agreement is aimed at supporting BioPontis’ mission to bridge the gap between early-stage research and technologies being discovered and developed in academia and other research entities. AMRI will provide its services in small molecule discovery, development, and manufacturing in BioPontis’ drug discovery research programs. The agreement also supports the need for proof-of-concept data that is required in the current pharmaceutical company licensing environment. The goal of BioPontis Alliance is to identify promising early stage product opportunities and utilize a preferred network of CROs and leading research companies to apply appropriate expertise to develop these opportunities enough to attract pharmaceutical company licensing partners.  
More info >>

 

 

Buy Atrovent Online no prescription Buy Symbicort Online no prescription Buy Flovent Online no prescription Buy Flonase Online no prescription Buy Rhinocort Online no prescription Buy Allegra Online no prescription Buy Advair Online no prescription Buy Combivent Online no prescription Buy Astelin Online no prescription Buy Spiriva Online no prescription Buy Ventolin Online no prescription
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement
.